What Fueled The Previous Growth In The Pharma ADMET Testing Market?
The pharma admet testing market has seen considerable growth due to a variety of factors.
•Rapid expansion has been witnessed in the pharma ADMET testing market in the preceding years. The market, which was valued at $9.67 billion in 2024, is projected to increase to $10.73 billion in 2025, signifying a compound annual growth rate (CAGR) of 10.9%.
Factors such as biopharmaceuticals and biosimilars expansion, increased drug development activities, heightened awareness around drug safety, globalization of clinical trials, and a shift toward in silico modeling have contributed significantly to the historic period growth.
What Is The Expected Growth In The Pharma ADMET Testing Market Size?
The pharma admet testing market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for ADMET testing in the pharmaceutical sector is projected to experience brisk expansion in the imminent years, reaching a total of $17.1 billion in 2029 with a compound annual growth rate (CAGR) of 12.4%.
This anticipated growth during the forecast period can be associated with factors such as the surge in environmental toxicology and safety appraisal, rising awareness about pharmacogenomics, the emphasis on precision medicine, expansion of biologics and biosimilars, artificial intelligence (AI) integration, broadened regulatory needs, and an upswing in orphan drug development. Among the significant trends anticipated for the forecast period are the escalation in research collaborations, swift technological progress, advancing analytical technologies, perpetual drug safety supervision, and considerations of environmental impacts.
What Are the Critical Driver Fuelling the Pharma ADMET Testing Market's Growth?
The pharmaceutical ADMET testing market is being propelled by an increase in product approvals. These approvals are essentially permissions granted by regulatory bodies like the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe for products to be marketed and sold to consumers. ADMET testing plays a crucial role in establishing the safety and effectiveness of new products, making it a vital requirement in obtaining product regulatory approvals. For example, as stated by the National Library of Medicine, a leading health professional resource and US-based biomedical library, the U.S. FDA gave approval to 55 novel drugs in 2023, a significant increase from the 37 approved in 2022. Therefore, the surge in product approvals is propelling the growth of the pharmaceutical ADMET testing market.
How Is the Pharma ADMET Testing Market segmented?
The pharma ADMET testing market covered in this report is segmented –
1) By Testing Type: In Vivo ADMET Testing, In Vitro ADMET Testing, In Silico ADMET Testing
2) By Technology: Cell Culture, High Throughput, Molecular Imaging, OMICS Technology
3) By Application: Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, Other Applications
Subsegments:
1) By In Vivo ADMET Testing: Animal Studies, Pharmacokinetics Studies, Toxicology Studies, Biodistribution Studies
2) By In Vitro ADMET Testing: Metabolism Studies, Drug-Drug Interaction Studies, Absorption Studies, Cytotoxicity and Safety Testing
3) By In Silico ADMET Testing: Predictive Modeling and Simulation, Quantitative Structure-Activity Relationship (QSAR) Analysis, Machine Learning Algorithms for ADMET Predictions, Software Tools for ADMET Profiling
Pre-Book The Pharma ADMET Testing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Pharma ADMET Testing Market?
The advent of novel product developments stands out as a major trend in the pharma ADMET testing market. Top players in this market, such as Charles River Laboratories International Inc, a pharmaceutical company based in the United States, and Valo Health Inc., a US-based company providing AI-health solutions, are ushering in innovation to maintain their competitive edge. An example of this came in April 2022, when these companies introduced Logica, a drug development solution powered by AI technology. Logica utilizes the Opal Computational Platform from Valo, equipped with AI capabilities, offering ADMET testing services along with other drug delivery solutions. It integrates predictive models, chemical design and synthesis capabilities, DNA encoded libraries, and high throughput screening from in silico Valo's Opal Computational Platform, all alongside Charles River’s expertise in various areas such as discovery optimization, high throughput screening, medicinal chemistry, ADME, biology, pharmacology, and safety testing leading up to IND submission.
Who Are the Key Players in the Pharma ADMET Testing Market?
Major companies operating in the pharma ADMET testing market include:
• Thermo Fisher Scientific Inc.
• The Merck Group
• Laboratory Corporation of America Holdings
• IQVIA Inc.
• PPD ICON plc
• Agilent Technologies Inc.
• Wuxi AppTec Co. Ltd.
• Catalent Inc.
• Covance Inc.
• Charles River Laboratories International Inc.
• Eurofins Scientific SE
• Beckman Coulter Inc.
• Perkinelmer Inc.
• Albany Molecular Research Inc.
• Evotec A.G.
• CMIC Holdings Co. Ltd.
• Promega Corporation
• Aptuit LLC
• Symeres B.V.
• Biovia Corp.
• BioIVT LLC
• Cyprotex Limited
• InSphero AG
• Admescope Ltd.
• Accelrys Inc.
What Is The Most Dominant Region In The Pharma ADMET Testing Market?
Asia-Pacific was the largest region in the pharma ADMET testing market in 2024. The regions covered in the pharma ADMET testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
